Your browser doesn't support javascript.
loading
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi, Giancarlo; Kappos, Ludwig; Selmaj, Krzysztof W; Bar-Or, Amit; Arnold, Douglas L; Steinman, Lawrence; Hartung, Hans-Peter; Montalban, Xavier; Kubala Havrdová, Eva; Cree, Bruce A C; Sheffield, James K; Minton, Neil; Raghupathi, Kartik; Ding, Ning; Cohen, Jeffrey A.
Afiliação
  • Comi G; Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: comi.giancarlo@hsr.it.
  • Kappos L; Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland.
  • Selmaj KW; Center for Neurology, Lodz, Poland; Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Arnold DL; NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
  • Steinman L; Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
  • Hartung HP; Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany.
  • Montalban X; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Kubala Havrdová E; Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic.
  • Cree BAC; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Sheffield JK; Department of Clinical Development, Celgene Corporation, Summit, NJ, USA.
  • Minton N; Drug Safety, Celgene Corporation, Summit, NJ, USA.
  • Raghupathi K; Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
  • Ding N; Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
  • Cohen JA; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Lancet Neurol ; 18(11): 1009-1020, 2019 11.
Article em En | MEDLINE | ID: mdl-31492651
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Esclerose Múltipla Recidivante-Remitente / Interferon beta-1a / Imunossupressores / Indanos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Esclerose Múltipla Recidivante-Remitente / Interferon beta-1a / Imunossupressores / Indanos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article